Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ACETAMINOPHEN vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Management of moderate to moderately severe pain (FDA approved),Off-label: acute pain, postoperative pain
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Oxycodone is extensively metabolized in the liver via CYP3A4 (primarily) and CYP2D6 (minor) to noroxycodone, oxymorphone, and other metabolites. Acetaminophen is metabolized in the liver mainly via glucuronidation and sulfation with a minor CYP2E1 pathway producing toxic NAPQI.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Oxycodone: 38-45% (primarily to albumin). Acetaminophen: 10-25% (minimal binding).
94% bound to albumin and alpha-1-acid glycoprotein
Oxycodone: 2.6-3.0 L/kg (wide distribution into tissues). Acetaminophen: 0.9-1.0 L/kg (uniformly distributed in body fluids).
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral immediate-release: oxycodone 60-87%, acetaminophen 68-88%. Oral extended-release: oxycodone 60-87% (less variable). Rectal: variable (unspecified for this combination).
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: acetaminophen no change, oxycodone consider 75% of usual dose; Cr Cl 10-29 m L/min: acetaminophen extend interval to q6h, oxycodone consider 50% of usual dose; Cr Cl <10 m L/min: acetaminophen avoid or 650 mg q8h, oxycodone 50% of usual dose; hemodialysis: acetaminophen 650 mg q8h, oxycodone 25-50% of usual dose.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh A: no adjustment; Child-Pugh B: oxycodone reduce dose by 50%, acetaminophen maximum 2000 mg/day; Child-Pugh C: oxycodone reduce dose by 75%, acetaminophen maximum 2000 mg/day; severe hepatic impairment: avoid acetaminophen component.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Children ≥6 months: 0.05-0.15 mg/kg oxycodone (based on oxycodone component) every 4-6 hours, maximum single dose 5 mg; acetaminophen 10-15 mg/kg/dose, maximum 75 mg/kg/day (up to 4000 mg/day). Weight-based oxycodone not to exceed adult dose.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Start at 50% of adult dose (oxycodone 2.5-5 mg every 6 hours), titrate cautiously; maximum acetaminophen 3000 mg/day due to decreased hepatic reserves; monitor for renal impairment and avoid if Cr Cl <30 m L/min.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; accidental ingestion may be fatal; risk of hepatotoxicity with acetaminophen overdose.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; hepatotoxicity (acetaminophen); severe hypotension; adrenal insufficiency; seizures; increased risk of overdose in patients with head injury or COPD.
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known or suspected gastrointestinal obstruction; severe hepatic impairment (acetaminophen).
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
Avoid alcohol consumption; increases risk of hepatotoxicity from acetaminophen and potentiates CNS depression. Grapefruit juice may increase oxycodone absorption; avoid concurrent use. High-fat meals can delay oxycodone peak concentration, potentially reducing rapid pain relief. No specific restrictions with other foods.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Second/third trimester: Chronic use may cause fetal opioid dependence, leading to neonatal abstinence syndrome (NAS). Late third trimester: Risk of respiratory depression in neonate if used near delivery.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Excreted into breast milk in low concentrations. M/P ratio for oxycodone: 3.2:1; acetaminophen: approximately 1.0. Considered compatible with breastfeeding with caution; monitor infant for sedation and feeding difficulties. Avoid if maternal codeine use due to CYP2D6 ultrarapid metabolism concerns (though oxycodone less affected).
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
No standard dose adjustment required for maternal pharmacokinetic changes. Increased renal clearance in pregnancy may slightly reduce acetaminophen levels, but therapeutic effect maintained. Oxycodone metabolism via CYP3A4 and 2D6; pregnancy-induced enzyme changes may alter clearance, but clinical significance unclear. Use lowest effective dose, avoid NSAIDs if co-prescribed.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Maximum daily acetaminophen dose is 4000 mg from all sources; prescribed combination tablets contribute to this limit. Oxycodone immediate-release duration is 3-6 hours; avoid crushing extended-release formulations. Both components have abuse potential; screen for opioid use disorder. In renal impairment, adjust dosing interval for oxycodone; avoid in Cr Cl <30 m L/min. In hepatic impairment, the acetaminophen component may be hepatotoxic; avoid in severe disease. Coadministration with serotonergic agents may precipitate serotonin syndrome. Naloxone is the reversal agent for oxycodone; acetylcysteine for acetaminophen overdose.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medications) to avoid exceeding the maximum daily dose of 4000 mg.,Avoid alcohol while taking this medication; liver damage risk increases with alcohol use.,Do not crush, break, or chew tablets; swallow whole to avoid rapid release of oxycodone.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Store securely out of sight and reach of children; dispose of unused medication via a drug take-back program.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ACETAMINOPHEN vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
OXYCODONE AND ACETAMINOPHEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ACETAMINOPHEN and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ACETAMINOPHEN is: Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ACETAMINOPHEN and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ACETAMINOPHEN is classified as Category D/X. First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.